In today’s briefing:
- Aequitas: Zhipu Placement – Back for Another US$5bn
- MiniMax Group Inc. (100 HK): Unlock Absorbed — Reload Window Now Open
- Aequitas: Transwarp Technology A/H Listing – Demanding Valuation With Slower Growth
- Guotai Junan International (1788 HK): Synthetic Expert Call Transcript (11 Sep 2026)
- Alibaba Group’s $100 Billion Cloud Ambition: Can AI Deliver The Payoff?
- GenScript Biotech (1548 HK): Synthetic Expert Call Transcript (11 Sep 2026)
- China International Capital (601995 CH) Post-Merger Tactical Outlook / Risks
Aequitas: Zhipu Placement – Back for Another US$5bn
- Z.AI (2513 HK) (aka Knowledge Atlas/Zhipu) is looking to raise around US$2bn via issuing shares and another US$3bn via CBs. The company had raised US$4bn in July 2026.
- Zhipu is one of the leading players in China’s domestic LLM space. Its IPO linked lockup had recently expired.
- In this note, we will talk about the placement and run the deal through our ECM framework.
MiniMax Group Inc. (100 HK): Unlock Absorbed — Reload Window Now Open
- Five-For-Five on initiation. We started BULLISH at HK$230.20 on 6 August, flagged HK$300 as trim, and identified September’s unlock as entry, not exit. The stock followed cleanly as expected.
- A secondary selloff, separate from the unlock, saw huge declines: July’s placing price, 21% below fair value, and 13.4x FY2028E EV/revenue. Margins cleared discipline; MSCI inclusion approaches. Thesis unchanged.
- Re-Enter. Buy at HK$267.80. Add aggressively below HK$260. Maximum position below HK$240. Do not chase above HK$300. Position for the November MSCI event by end-October.
Aequitas: Transwarp Technology A/H Listing – Demanding Valuation With Slower Growth
- Transwarp Technology (688031 CH) , an AI infrastructure software provider, aims to raise up to US$109m in its H-share listing.
- Transwarp Technology (Shanghai) Co (TTC) is an AI infrastructure software provider in China. TTC enables enterprises to efficiently build AI infrastructure software.
- We have looked at the PHIP updates in our previous note. In this note, we talk about the IPO pricing.
Guotai Junan International (1788 HK): Synthetic Expert Call Transcript (11 Sep 2026)
- The 10% Objection Rule is the Principal Execution Risk: Because the scheme of arrangement requires cancelling 3.29 billion shares (representing 34.5% of issued share capital), the blocking threshold under the Hong Kong Takeovers Code’s 10% objection rule is exceptionally low at just 3.45% of total outstanding shares. A concentrated block of activist arbitrageurs or passive funds could easily derail the transaction, though the 44.2% premium and 1.8x P/B valuation are structurally calibrated to preempt such dissent.
- Out-of-the-Money Exchangeable Bonds (EBs) Force Parent Cash Outlay: The HK$3.88 billion zero-coupon exchangeable bonds due 2032 carry an exchange price of HK$4.24, rendering them significantly out-of-the-money relative to the HK$3.00 take-private offer. Under Rule 13 of the Takeovers Code, the offeror must make a comparable proposal, which in practice will trigger delisting put options, forcing the parent to redeem the bonds at par and pushing the maximum cash required for the transaction to HK$12.6 billion.
- Severe Retention Risks in Impending Post-Merger Integration: The privatization of Guotai Junan International (GTJAI) is the second phase of Guotai Haitong’s offshore restructuring, following the 2024 privatization of Haitong International (HTI). Merging these two highly divergent platforms will trigger major cultural and operational friction, particularly as the rigid risk-averse Shanghai SOE parent seeks to dismantle GTJAI’s historical operational autonomy and compress the flexible compensation structures necessary to retain key wealth management talent.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
Alibaba Group’s $100 Billion Cloud Ambition: Can AI Deliver The Payoff?
- Alibaba Group reported mixed financial results, with strong cloud and artificial intelligence growth offset by profitability pressure from heavy investment.
- Total revenue reached RMB 269 billion, up 9% year-over-year, driven largely by a 45% increase in Alibaba Cloud external revenue, marking the 22nd quarter of acceleration.
- AI-related cloud products sustained triple-digit growth for the 12th consecutive quarter and reached an annualized revenue run rate of RMB 49.5 billion, or approximately USD 7.3 billion.
GenScript Biotech (1548 HK): Synthetic Expert Call Transcript (11 Sep 2026)
- Strong Core Profitability Inflection: GenScript’s Life Science Group (LSG) has crossed a key utilization threshold, with 1H 2026 adjusted operating profit surging 102.8% to US$94.0 million on a 28.8% revenue increase. This operating leverage is heavily driven by high-throughput automation and the doubling of high-margin AI-driven protein orders.
- Capital Raise Driven by Cap Table Restructuring: The newly announced US$300 million primary placement at HK$30.50 per share is strategically timed to offset the US$225.1 million cash outlay used to buy back Hillhouse Capital’s preferred shares in ProBio. This restructuring cleans up ProBio’s cap table ahead of its newly approved HKEX Main Board spin-off.
- Bifurcated Competitive Landscape: GenScript retains an 80%+ win rate against Twist Bioscience and IDT for long-chain, highly complex genes (>10kb) due to proprietary error-correction algorithms, but loses on pure price ($0.003/base) to Twist for standard, low-complexity gene fragments (<1.5kb). Geopolitical overhang from the BIOSECURE Act is driving US biopharma clients to multi-source, capping GenScript’s near-term US market share expansion.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
China International Capital (601995 CH) Post-Merger Tactical Outlook / Risks
- As reported by Brian Freitas global index trackers will start to buy China International Capital (601995 CH) at the close on Monday September 14th.
- Tri-Party share-swap merger absorbing Dongxing Securities (601198 CH) and Cinda Securities (601059 CH) was approved by CSRC in early September 2026.
- CICC is trading at good discount value, mildly oversold, according to our model, but it could go lower before global index trackers buy and push the price higher.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
